Perspective Therapeutics (CATX) – Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Perspective Therapeutics (NYSE: CATX):

• 3/19/2025 – Perspective Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
• 3/17/2025 – Perspective Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
• 3/13/2025 – Perspective Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $10.00 price target on the stock.
• 3/10/2025 – Perspective Therapeutics was upgraded by analysts at Brookline Capital Management to a “strong-buy” rating.
• 3/7/2025 – Perspective Therapeutics is now covered by analysts at Scotiabank. They set a “sector outperform” rating and a $15.00 price target on the stock.
• 3/6/2025 – Perspective Therapeutics was upgraded by analysts at Lifesci Capital to a “strong-buy” rating.
• 3/4/2025 – Perspective Therapeutics was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating.
• 2/5/2025 – Perspective Therapeutics was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating.
• 1/24/2025 – Perspective Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.

Perspective Therapeutics Trading Down 1.0 %

CATX traded down $0.03 during trading on Friday, hitting $2.47. 178,355 shares of the stock traded hands, compared to its average volume of 983,678. The firm has a 50-day moving average of $3.05 and a 200 day moving average of $6.96. Perspective Therapeutics, Inc. has a 12-month low of $2.32 and a 12-month high of $19.05.

Institutional Investors Weigh In On Perspective Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CATX. FMR LLC lifted its position in shares of Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after purchasing an additional 5,370,392 shares during the period. Millennium Management LLC purchased a new stake in shares of Perspective Therapeutics in the 4th quarter worth about $4,132,000. State Street Corp lifted its position in shares of Perspective Therapeutics by 119.6% in the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares during the period. Octagon Capital Advisors LP lifted its position in shares of Perspective Therapeutics by 62.1% in the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after purchasing an additional 882,528 shares during the period. Finally, Affinity Asset Advisors LLC lifted its position in shares of Perspective Therapeutics by 160.0% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock worth $4,147,000 after purchasing an additional 800,000 shares during the period. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.